Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study
M Kolodziej1, C Goetz2, P Di Fazio2
1Department of Neurosurgery, University Hospital Giessen, Giessen, Germany.
Abstract:
Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non small-cell lung cancer and lymphomas. It targets CDK2, 7 and 9 preferentially, which are also overexpressed in glioblastoma. Τherefore, the biological effects of roscovitine in glioblastoma cell lines were investigated. Glioblastoma A172 and G28 cell lines were incubated with serial concentrations of roscovitine for 24-120 h. Proliferation was measured using the xCELLigence Real-Time Cell Analyzer, an impedance‑based cell viability system. Cell cycle distribution was assessed by flow cytometry and gene expression was quantified by quantitative RT-PCR and western blot analysis. Roscovitine exhibited a clear dose-dependent anti‑proliferative and pro‑apoptotic effect in the A172 cell line, while G28 cells showed a anti-proliferative effect only at 100 µM. The results of the flow cytometric (FACS) analysis revealed a dose-dependent increase of the G2/M and sub-G1 fractions in A172 cells, while G28 cells responded with an elevated sub-G1 fraction only at the highest concentration. Roscovitine led to a dose‑dependent decrease of transcripts of p53, CDK 7 and cyclins A and E and an increase of >4-fold of p21 in A172 cells. In G28 cells, a dose‑dependent induction of CDK2, p21 and cyclin D was observed between 10 and 50 µM roscovitine after 72 h, however, at the highest concentration of 100 µM, all investigated genes were downregulated. Roscovitine exerted clear dose-dependent anti-proliferative and pro-apoptotic effects in A172 cells and less distinct effects on G28 cells. In A172 cells, roscovitine led to G2/M arrest and induced apoptosis, an effect accompanied by induced p21 and a reduced expression of CDK2, 7 and 9 and cyclins A and E. These effects requre further studies on a larger scale to confirm whether roscovitine can be used as a therapeutic agent against glioblastoma.
Insights
Roscovitine, a cyclin-dependent kinase inhibitor, shows anti-cancer effects in glioblastoma cells. It reduced proliferation and induced apoptosis in A172 cells, with varied effects on G28 cells, warranting further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Cyclin-dependent kinases (CDKs) are frequently overexpressed in glioblastoma.
- Roscovitine is a purine analogue and CDK inhibitor with known anti-cancer properties.
Purpose of the Study:
- To investigate the biological effects of roscovitine on glioblastoma cell lines (A172 and G28).
- To assess roscovitine's impact on glioblastoma cell proliferation, cell cycle, and gene expression.
- To determine the potential of roscovitine as a therapeutic agent for glioblastoma.
Main Methods:
- Glioblastoma cell lines (A172, G28) were treated with varying concentrations of roscovitine.
- Cell proliferation was measured using the xCELLigence Real-Time Cell Analyzer.
- Cell cycle distribution, gene expression (RT-PCR, Western blot) were analyzed.
Main Results:
- Roscovitine demonstrated dose-dependent anti-proliferative and pro-apoptotic effects in A172 cells.
- G28 cells showed anti-proliferative effects only at the highest concentration (100 µM).
- Roscovitine induced G2/M arrest and apoptosis in A172 cells, altering expression of key cell cycle regulators.
Conclusions:
- Roscovitine exhibits significant anti-cancer activity in A172 glioblastoma cells.
- The drug's effects on G28 cells were less pronounced, suggesting differential sensitivity.
- Further large-scale studies are needed to evaluate roscovitine as a glioblastoma therapeutic.
